Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline: European Commission Authorizes Nimenix

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 02:24pm CEST

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
07/21DJGLAXOSMITHKLINE : FDA Approves Injectable Form Of Glaxo's Benlysta
07/21GLAXOSMITHKLINE PLC : half-yearly earnings release
07/21 GLAXOSMITHKLINE : GSK receives FDA approval for a new self-injectable formulatio..
07/21 GlaxoSmithKline's new CEO prepares to trim drug pipeline
07/21 GLAXOSMITHKLINE : GSK Submits EU Filing for Extended Use of Relvar Ellipta in Pa..
07/21 GLAXOSMITHKLINE : GSK announces Board and Committee changes
07/20 GLAXOSMITHKLINE : Reports from GlaxoSmithKline plc Advance Knowledge in Asthma (..
07/20 GLAXOSMITHKLINE : Patent Issued for Prodrug of 1,1'-(1,6-Dioxo-1,6-Hexanediyl)bi..
07/20 GLAXOSMITHKLINE : Reports Findings in Myocardial Infarction (No increased risk o..
07/20 GLAXOSMITHKLINE : Investigators from GlaxoSmithKline plc Report New Data on Brea..
More news
News from SeekingAlpha
07/21 FDA OKs self-injectable formulation of Glaxo's SLE med Benlysta
07/21 Glaxo submits marketing application in Europe for extended use of Relvar Elli..
07/21 United Therapeutics Losing The Crown Jewels; 20% EPS Downgrades Ahead
07/21 Sirukumab's Panel And U.S. Decision For Medicines Company
07/19 Emergent Bio buys anthrax biologic raxibacumab from Glaxo for up to $96M
Financials ( GBP)
Sales 2017 30 113 M
EBIT 2017 8 330 M
Net income 2017 4 356 M
Debt 2017 13 962 M
Yield 2017 4,95%
P/E ratio 2017 18,05
P/E ratio 2018 15,83
EV / Sales 2017 3,10x
EV / Sales 2018 2,98x
Capitalization 79 432 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,8  GBP
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE3.39%103 206
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.5.46%221 492
NOVARTIS9.72%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303